|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits Na+/ K+ AT Pase
|
|
gptkbp:appointed_by
|
oral tablet
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Lanoxin
|
|
gptkbp:can_be_used_with
|
gptkb:ACE_inhibitors
anticoagulants
beta-blockers
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
ventricular fibrillation
hypersensitivity to digoxin
|
|
gptkbp:developed_by
|
gptkb:Digitalis_purpurea
|
|
gptkbp:discovered_by
|
gptkb:1785
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral solution
injectable solution
|
|
gptkbp:historical_event
|
treatment for arrhythmias
treatment for dropsy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
digoxin
|
|
gptkbp:ingredients
|
C41 H64 O14
|
|
gptkbp:interacts_with
|
gptkb:amiodarone
gptkb:quinidine
gptkb:verapamil
diuretics
|
|
gptkbp:is_atype_of
|
C01 A A05
|
|
gptkbp:is_available_in
|
tablets
liquid form
capsules
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_monitored_by
|
renal function
serum digoxin levels
|
|
gptkbp:is_used_for
|
gptkb:atrial_fibrillation
heart failure
|
|
gptkbp:lifespan
|
36 to 48 hours
|
|
gptkbp:metabolism
|
kidneys
|
|
gptkbp:research_focus
|
pharmacokinetics
heart disease
drug interactions
cardiac arrhythmias
|
|
gptkbp:side_effect
|
dizziness
nausea
vomiting
increases myocardial contractility
visual disturbances
decreases heart rate
|
|
gptkbp:treatment
|
supraventricular tachycardia
|
|
gptkbp:type_of
|
20830-75-5
|
|
gptkbp:used_in
|
geriatric medicine
pediatric cardiology
|
|
gptkbp:weight
|
780.94 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Forteo
gptkb:Nexium
|
|
gptkbp:bfsLayer
|
4
|